Budget Impact Analysis of the use of emicizumab for bleeding prophylaxis in patients with Hemophilia A with inhibitors in the Brazilian Health System
Hemophilia A is a hereditary hemorrhagic disorder characterized by deficiency or dysfunction of the coagulation protein factor VIII. The standard therapy consists of factor VIII replacement, which can lead to the development of neutralizing antibodies (inhibitors), a major complication that implies...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Instituto Nacional de Assistência Farmacêutica e Farmacoeconomia,
2022-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Hemophilia A is a hereditary hemorrhagic disorder characterized by deficiency or dysfunction of the coagulation protein factor VIII. The standard therapy consists of factor VIII replacement, which can lead to the development of neutralizing antibodies (inhibitors), a major complication that implies a burden on patient health and the healthcare system because of the decreased quality of life and further costs with treatment. The current work was to assess the budget impact of a bispecific monoclonal antibody, for patients with inhibitors, considering the Brazilian Public System perspective. Results demonstrated high efficacy on preventing bleeds and savings of R$ 1.5 billion in five years. |
|---|---|
| Item Description: | 10.22563/2525-7323.2022.v1.s3.p.21-30 2525-5010 2525-7323 |